interaction is critical to prevent OIS in PanINs and allow progression to PDAC.
INTRODUCTION
KRAS mutations drive over 90% of pancreatic cancer, a disease with a dismal overall 5-year survival rate of only 9% 1 . Like all RAS GTPases KRAS is a molecular switch that transduces extracellular mitogenic signals by cycling between an active GTP-bound and an inactive GDP-bound state. Proteins that regulate the nucleotide loading of RAS, like GTPase activating proteins (GAPs) or guanine exchange factors (GEFs) recruit RAS to the plasma membrane in response to activated (i.e., phosphorylated) growth factor receptors, like EGFR [2] [3] [4] .
Recurrent oncogenic driver mutations in RAS decrease terminal phosphate cleavage, resulting in the accumulation of its active GTP-bound form at the plasma membrane. Constitutively active RAS leads to aberrant signaling activities through interactions with multiple effector proteins at the plasma membrane 2, 3, 5 .
Genetically engineered mouse models (GEMMs) of pancreatic cancer were developed by expression of a single oncogenic KRAS G12D allele in the mouse exocrine pancreas. In this model, pre-invasive pancreatic intraepithelial (PanINs) lesions progress to pancreatic adenocarcinoma (PDAC) reflective of the human disease 6 . Further, the pathophysiology and site of metastases observed in this model closely mimic human pancreatic cancer, underscoring its applicability for studying the human disease. Use of such GEMMs have been instrumental in defining the key events that characterize PanIN development and PDAC progression [7] [8] [9] . Of particular relevance is the observation that EGFR, the upstream modulator of RAS signaling, is essential for KRAS
G12D
-driven PanIN development 10, 11 , despite mutual exclusivity of EGFR and RAS aberrations in cancer. However, the requirement for EGFR at the early stage of PanIN development has not translated to successful treatment of pancreatic cancer 12, 13 . Despite our understanding of the signaling events triggered by oncogenic RAS, targeting KRAS remains a challenging prospect 4, 14 .
To investigate potential additional modulators of RAS-mediated oncogenesis, we previously performed a screen for direct interactors of RAS in a panel of cancer cell lines and identified a direct interaction between KRAS and Argonaute 2 (AGO2), independent of KRAS mutation status 15 . The N-terminal domain of AGO2 was found to bind the regulatory Switch II region in RAS and was required for oncogenic KRAS-driven cellular transformation. Notably, AGO2 RNA silencing activity was inhibited in cells expressing mutant RAS compared to wildtype RAS, suggesting that KRAS binding, and not the RNAi function of AGO2, was essential for oncogenesis. Interestingly, Shen et al. had previously identified a functional interaction between EGFR and AGO2 16 . Their study showed that EGFR phosphorylates AGO2 at tyrosine 393 under hypoxic stress to alter its RNAi function.
Given these previous observations, we have employed established mouse models of pancreatic cancer to determine the in vivo requirement of AGO2 in pancreatic cancer development in the context of KRAS signaling. Our data show that oncogenic KRAS-initiated PanIN formation is reliant on EGFR and wild-type RAS signaling, independent of AGO2.
Strikingly, however, we identify a critical dependence on AGO2 for PanIN progression to PDAC, bypassed by loss of p53. While defining an essential role for AGO2 in PDAC progression, we also further our understanding of how the KRAS-AGO2 interaction is regulated through EGFR activation. Disruption of the oncogenic KRAS-AGO2 association may, therefore, represent a novel point of therapeutic intervention to prevent pancreatic cancer progression.
RESULTS

Loss of AGO2 does not affect normal pancreas development or early stage PanIN formation in KRAS G12D mice
To investigate the role of AGO2 in the development of pancreatic cancer in vivo, we employed the genetically engineered mouse model of pancreatic cancer initiated by a conditionally activated allele of KRAS (ref. 6 ), KRAS LSL-G12D/+ (KRAS G12D , shown in Fig. 1a ).
Crossing KRAS G12D mice with animals harboring Cre recombinase knocked into the pancreasspecific promoter, p48 (p48Cre), yields KRAS
G12D
;p48Cre mice that develop pancreatic intraepithelial neoplasia (PanINs) precursor lesions beginning around 8 weeks of age 6 . Over time, these PanINs progress to pancreatic ductal adenocarcinoma (PDAC) and develop metastases, faithfully mimicking the human disease. In order to evaluate the potential consequences of AGO2 ablation in this model, we generated transgenic mice with both KRAS G12D and conditionally deleted allele(s) of AGO2 (ref. 17 ) (Fig. 1a) . Fig. 1a) . Further, qRT-PCR analysis showed significant reduction in
;p48Cre mice ( Supplementary Fig. 1b) , confirming Cremediated mutant KRAS activation with concomitant loss of AGO2 expression in the pancreas.
Histological analysis of pancreata from mice with Cre-mediated AGO2 ablation (AGO2 fl/fl ; p48Cre) showed normal morphology (Fig. 1b , left panels) with no differences in pancreatic weight compared to pancreata from AGO2 +/+ ;p48Cre mice ( Supplementary Fig. 1c ). This suggests that loss of AGO2 in the acinar cells of the exocrine compartment does not grossly interfere with pancreas development. Immunohistochemical (IHC) staining with a monoclonal antibody specific to AGO2 ( Supplementary Fig. 2 Fig. 3a-b) . ;p48Cre mice, suggestive of a higher tumor burden in mice with at least one functional allele of AGO2 (Fig. 1d) ;p48Cre pancreata, but these lesions invariably showed AGO2 expression ( Supplementary Fig. 4) , indicative of likely escape from Cre recombination, as has been previously noted in other contexts 11, 20 .
Loss of AGO2 in
In order to further examine the effect of AGO2 loss on tumor-free survival, a cohort of transgenic mice was monitored over 500 days. ;p48Cre) had survived at the cut-off time point of 500 days (Fig. 1f) . PDAC was observed in pancreata of all mice that expressed AGO2 (wild-type or heterozygous expression), but mice deficient for AGO2 developed only early PanIN precursor lesions without progression to PDAC (Fig. 1g) .
Necropsies of experimental mice from the different genotypes were also assessed for grossly visible metastases and abnormal pathologies 22 (Supplementary Fig. 6 ). By contrast, phospho-ERK staining was not uniformly detected in the PDACs from
;p48Cre mice. Thus, oncogenic KRAS-driven progression from PanIN to PDAC requires AGO2 expression to block OIS in mice. We also observed OIS with high levels of phospho-ERK staining in PanINs from human pancreatic tissue (Fig. 2d) , suggesting that similar mechanisms may block PDAC development in human tissue.
Concomitant oncogenic KRAS activation and p53 loss overcome the requirement for
AGO2 in PDAC progression
Since p53 loss leads to evasion of senescence 25 ;Trp53 fl/+ ;p48Cre genotypes showed no significant differences (Fig. 3a) . PDAC and metastatic spread were also similar in all of the genotypes analyzed (Fig. 3b) . IHC confirmed that AGO2 ablation was efficient (Fig. 3c) (Fig. 4b) , and this increase was statistically significant (Fig. 4c) . These data show that AGO2 protein levels are elevated with disease progression and suggest an important role for AGO2 in pancreatic cancer development in humans.
Considering that active RAS is known to localize to the plasma membrane 2,28 , we tested if RAS and the RAS-AGO2 interaction could be localized at the plasma membrane in the mouse models and human tissues. Since most commercial KRAS-specific antibodies have been shown to be unsuitable for IHC or immunofluorescence (IF) 29 , we tested RAS10, a pan-RAS monoclonal antibody that showed specific staining, as determined by the total loss of signal in RASless MEFs ( Fig. 5a and Supplementary Fig. 7a-b) . Surprisingly, relative to the surrounding normal tissue, IHC and IF analysis of mouse pancreatic tissues with this antibody detected high membranous RAS expression within the PanINs (Fig. 5b) , indicative of activated RAS. Notably, pre-incubation of the antibody with RAS peptides spanning the antibody epitope abrogated RAS staining (Fig. 5c) , further demonstrating the specificity of the antibody to detect RAS. To corroborate the finding that RAS IHC and IF staining were primarily restricted to oncogenic KRAS-driven PanINs, we performed RNA in situ hybridization (RNA-ISH) using Fig. 7c ). As shown in Supplementary Fig. 7d , we observed KRAS transcripts restricted to the ducts of pancreatic lesions. The elevated KRAS transcript expression in PanINs is consistent with a recent study reporting increased oncogenic KRAS transcripts in engineered mouse models 30 . We also validated the AGO2 monoclonal antibody by using pancreatic tissue from AGO2 fl/fl ;KRAS
KRAS-targeted RNA probes (Supplementary
G12D
;p48Cre mice ( Together these data indicate that during pancreatic cancer development, AGO2 localizes at the plasma membrane, the site of RAS activity 2, 28 , and substantiates a role for AGO2 in the progression of PanINs to PDAC.
Loss of AGO2 and its impact on the EGFR-RAS signaling axis
The data above place AGO2 and RAS together at the plasma membrane during PDAC progression. Therefore, we next sought to explore how AGO2 may mediate alteration of RAS signaling pathways. We specifically focused on the EGFR-RAS signaling axis for two reasons:
1) EGFR has been shown to be essential for PanIN formation in the KRAS
G12D
-driven pancreatic mouse model that we have used 10, 11, 34 , and 2) EGFR activation has been shown to directly inhibit AGO2 function through phosphorylation of its tyrosine 393 residue 16 . ;p48Cre genotypes showed a marked increase in AGO2 levels relative to normal pancreata ( Supplementary Fig. 9 ) concordant with IF analysis (Fig. 5e) . Also, consistent with published studies 10, 11 , total EGFR levels were elevated in KRAS G12D mice irrespective of the AGO2 genotype (Supplementary Fig. 9 ).
However, in early PanINs initiated by oncogenic KRAS, significantly higher levels of phospho-EGFR (Y1068) were observed in pancreatic tissues of AGO2 fl/fl ;KRAS
;p48Cre mice ( Fig. 6a and Supplementary Fig. 9 ;p48Cre mice (Fig. 6b) . IHC of total EGFR showed no significant difference in expression in pancreatic tissues between the two genotypes ( Fig. 6b and Supplementary Fig. 10a ). As previously noted, irrespective of AGO2 genotype, lesions from later time points showed a marked reduction in total EGFR levels 10, 11 in mouse (and with disease progression in human tissue), further supporting the significance of EGFR signaling in the early stages of disease ( Supplementary Fig. 10a-b) . Importantly, immunoblot analysis showed that EGFR activation was accompanied with a remarkable increase in total RAS levels but not oncogenic KRAS G12D levels ( Fig. 6a and Supplementary   Fig. 9 ), raising an intriguing possibility that growth factor activation involves signaling along the EGFR-wild-type RAS axis in early stage PanINs.
To investigate this further, we isolated pancreatic ducts from 12-week old ;p48Cre mice and cultured them as organoids 35 in the absence of EGF (Supplementary Fig. 11 ). Immunoblot analysis showed increased levels of phospho-EGFR and total RAS in the organoids with AGO2 loss, while KRAS G12D expression showed no change (Fig. 6c) , mirroring the observations from pancreatic tissue lysates. Remarkably, the total RAS levels (which includes both wild-type and mutant RAS), as well as total RAS-GTP, were higher in organoids deficient in AGO2.
To probe if AGO2 loss activates wild-type RAS even in the absence of mutant KRAS, we performed immunoblot analysis and RAS activation assays using AGO2 -/-MEFs that do not harbor any form of oncogenic RAS 36 . As shown in Fig. 6d , AGO2 -/-MEFs also exhibit increased phospho-EGFR and wild-type RAS levels along with elevated wild-type RAS-GTP levels, which were significantly reduced when rescued with AGO2. Given that AGO2 is a direct phosphorylation substrate of the EGFR kinase 16 , our experiments define a previously unknown reverse feedback up-regulation of phospho-EGFR via AGO2 that controls RAS activation [37] [38] [39] [40] .
AGO2 Y393 phosphorylation by EGFR disrupts wild-type, but not mutant, KRAS-AGO2 interaction at the membrane
Considering that the loss of AGO2 expression leads to activation of both EGFR and wildtype RAS (Fig. 6) Fig. 7a and Supplementary Fig. 12a-b) . In stark contrast, EGF stimulation of cells harboring oncogenic KRAS, including A549 (KRAS
G12S
), MIA PaCa-2 (KRAS
G12C
), and Capan-1 (KRAS
G12V
), retained binding of endogenous KRAS and AGO2 despite activation of the EGFR/MAPK/AKT pathway ( Fig. 7b and Supplementary Fig. 12c) . Disruption of the wild-type RAS-AGO2 interaction was also observed when HEK293 (KRAS WT ) cells expressing FLAGtagged AGO2 were stimulated with EGF; the interaction was rescued by treatment of cells with the EGFR kinase inhibitor, erlotinib (Fig. 7c) . This strongly suggests that EGFR kinase activity was critical for the disruption of the wild-type KRAS-AGO2 interaction. In contrast, DLD-1 cells harboring mutant KRAS G13D showed no loss of KRAS and AGO2 association either by EGF treatment, or by EGFR kinase inhibition with erlotinib (Fig. 7d) .
To test if the previously identified site of EGFR-mediated phosphorylation 16 on AGO2 at tyrosine 393 has a role in binding to KRAS, we analyzed the ability of a phosphorylationdeficient AGO2 Y393F mutant to bind RAS under different conditions. In HEK293 (KRAS WT ) cells, EGF stimulation led to dissociation of wild-type AGO2 from RAS, but the AGO2 Y393F mutant continued to bind RAS with or without EGFR activation (Fig. 7e) , indicating that phosphorylation of this residue is critical for dissociation. Expression of these AGO2 constructs in MIA PaCa-2
(KRAS
G12S
) cells showed no discernible change in RAS binding upon EGFR activation (Fig. 7f) .
To track the localization of the RAS-AGO2 interaction upon growth factor activation, we performed PLA on cells expressing wild-type or mutant KRAS. The use of either RAS or AGO2
antibodies alone did not show signals for the RAS-AGO2 PLA (Supplementary Fig. 13a ).
Interestingly, serum starved PC3 cells showed increased membrane localization of both RAS and AGO2 proteins contributing to the dramatic increase in membrane localized RAS-AGO2
PLA signals under these conditions (Fig. 7g, upper panels) . RAS-AGO2 interaction PLA signals were significantly reduced upon EGF stimulation and restored to levels observed under serum sufficient conditions. IF analyses also showed a similar pattern of RAS-AGO2 co-localization under these different culture conditions (Supplementary Fig. 13b) . A similar pattern of RAS-AGO2 interaction PLA signals was observed in wild-type RAS expressing MCF-7 cells (Fig. 7g, panel I). In contrast, both HCT116 and H358 cells (Fig. 7g , panels II and III), expressing oncogenic forms of KRAS, showed higher basal levels of RAS-AGO2 PLA signals compared to wild-type RAS expressing cells that remained consistent under different cell culture conditions. This further corroborates results obtained above through co-IP analysis. Combined, these data suggest that the wild-type KRAS-AGO2 interaction at the membrane is sensitive to EGFRmediated phosphorylation of AGO2 Y393 , while the oncogenic KRAS-AGO2 interaction is unaffected by both EGFR activation status as well as AGO2 Y393 phosphorylation.
ARS-1620, a G12C inhibitor, disrupts the oncogenic KRAS-AGO2 interaction
Finally, we tested if direct targeting of oncogenic KRAS could affect the endogenous mutant KRAS-AGO2 interaction. Interestingly, the mutant KRAS-AGO2 interaction was disrupted when H358 (Fig. 8a) and MIA-PaCa-2 cells (Fig. 8b) , harboring KRAS G12C mutant alleles, were treated with ARS-1620 41 , a covalent G12C inhibitor. The disruption of endogenous KRAS G12C -AGO2 interaction in these cells was concentration dependent and reflects the differential sensitivities of the two cell lines to ARS-1620 42 . In a similar assay, ARS-1620 treatment had no effect on the KRAS G12D -AGO2 or KRAS wt -AGO2 interaction in Panc 05.04 cells (Fig. 8c) or HeLa cells (Fig. 8d) , respectively. Given that ARS-1620 binds an allosteric Switch II pocket (SW-IIP) 42 on GDP-loaded KRAS
G12C
, the disruption of the KRAS
-AGO2
binding provides orthogonal evidence that AGO2 makes contact with the Switch II region in KRAS. This data also proves that besides SOS, the easily detectable, endogenous membrane bound KRAS
-AGO2 interaction (Fig.7g) is an additional target of G12C inhibitors.
DISCUSSION
Genetically engineered mouse models have been extensively used to mirror the stepwise progression of human pancreatic cancer, starting with benign precursor lesions (PanINs) driven by mutant KRAS 9, 43, 44 . Here, using GEMM models of AGO2 loss, we propose that pancreatic cancer development involves two phases (Fig. 9a) (Fig. 9b) . Failure to detect bypass routes to oncogenesis, unlike the GEMM model with NOTCH2 loss 45 , highlights the robustness of OIS observed in the absence of AGO2.
The second phase of PDAC progression is AGO2 dependent, and the AGO2-KRAS interaction likely plays a predominant role (Fig. 9a) . AGO2 is found localized at the plasma membrane, a site not previously associated with RNA silencing activity [46] [47] [48] [49] . Importantly, we
show for the first time that AGO2 levels are increased in PDAC and metastases compared to PanIN lesions from patients, highlighting the relevance of AGO2 in clinical disease progression.
Increased RAS-AGO2 co-localization at the plasma membrane is also seen during PDAC progression in mice and humans, providing evidence for the role of AGO2 at the site of oncogenic KRAS activity. We hypothesize that this robust interaction between mutant KRAS and AGO2 overcomes the OIS block, facilitating the second phase of progression, from PanIN to PDAC. Loss of p53 precludes this requirement for AGO2 (Fig. 9c) , but RAS-AGO2 colocalization is retained in this model.
In addition to delineating a biphasic model of pancreatic cancer development, this study defines novel aspects of the EGFR-RAS-AGO2 signaling network, particularly regarding modulation of the RAS-AGO2 interaction. PLA provides the first evidence of direct RAS-AGO2 interaction at the plasma membrane within pancreatic lesions driven by oncogenic KRAS.
Interestingly, wild-type RAS expressing cells undergoing serum starvation also show increased RAS-AGO2 interaction at the membrane. This suggests that the membrane RAS-AGO2
association under conditions of stress (starvation or presence of oncogenic KRAS) allows finetuning of RAS signaling through growth factor receptor activation. Phosphorylation of AGO2 by EGFR simultaneously inhibits the last step of microRNA biogenesis 16 and activates RAS at the plasma membrane 50 , a previously unrecognized aspect of EGFR-RAS-MAPK signaling.
However, this observation is consistent with previously reported disruptions of other proteinprotein interactions through EGFR phosphorylation as a strategy to modulate RAS activation signals at the membrane [51] [52] [53] .
Our observation that EGF stimulation disrupts the wild-type KRAS-AGO2 interaction, but not the oncogenic KRAS-AGO2 interaction, is likely central to the critical requirement of EGFR signaling in PanIN formation 10, 11 . It is also intriguing that EGFR-mediated phosphorylation of AGO2 Y393 disrupts wild-type RAS binding in a manner reminiscent of AGO2-Dicer binding 16 .
However, AGO2-KRAS mutant binding remains unaffected by AGO2 phosphorylation status, underscoring the critical reliance of PDAC progression on this interaction. Notably, we find that a G12C covalent inhibitor can disrupt the mutant KRAS-AGO2 interaction. Altogether, our data suggest that abrogation of the oncogenic KRAS-AGO2 association at the plasma membrane may represent a novel therapeutic opportunity for pancreatic cancer treatment that warrants further investigation. ;p48Cre group indicate abnormal pathology observed at the indicated site and are addressed in further detail in Supplementary Fig. 5 . 
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METHODS
Mouse strains
LSL-KRAS
Histology, immunohistochemistry, and immunofluorescence
Paraffin-embedded tissues from mice were processed using standard methodology. Details of the primary antibodies used for IHC are provided in Supplementary Table 1 .
Immunohistochemistry and immunofluorescence staining were performed using standard 
Proximity Ligation Assay (PLA)
Cell lines were cultured in 8-well chamber slides. After the indicated treatment/stimulation, cells were fixed with 4% paraformaldehyde and then permeabilized using 0.1%Tween. Subsequent PLA staining was performed as per the protocol provided by the manufacturer (DUOlink kit, Millipore/Sigma). Mouse RAS10 and rabbit AGO2 antibodies, validated in this study, were used at 1:250 dilution to detect signals either alone or in combination. Negative controls were performed using either single antibody (Supplementary Fig. 13a ), Rasless MEFs (Supplementary Fig. 8d ), or tissue lacking AGO2 (Fig. 5d) . Images were obtained using the Nikon A1B inverted confocal microscope. For mouse tissue PLA, the paraffin-embedded sections were processed as for IF analysis. PLA was then performed using RAS10 or AGO2
antibodies, either alone or in combination, and imaged using the Nikon A1B confocal microscope.
Human TMA analysis
Pancreatic TMAs and frozen human tissue repositories were established by a pathologist (J.S.)
and developed at the Tissue and Molecular Pathology Core in the Department of Pathology, University of Michigan, after IRB approval. IHC scoring was performed by a pathologist (J.S.).
RNA in situ Hybridization (RNA-ISH)
RNA-ISH was performed to detect Kras mRNA on formalin-fixed paraffin-embedded (FFPE) tissue sections using the RNAscope 2.5 HD Brown kit (Advanced Cell Diagnostics, Newark, CA) and target probes against mouse Kras (412491). Mm-Ubc (mouse ubiquitin C) and DapB (Bacillus bacterial dihydrodipicolinate reductase) were used as positive and negative controls, respectively. FFPE tissue sections were baked for 1 hour at 60°C, deparaffinized in xylene twice for 5 minutes each, and dehydrated in 100% ethanol twice for 1 minute each, followed by air drying for 5 minutes. After hydrogen peroxide pre-treatment and target retrieval, tissue samples were permeabilized using Protease Plus and hybridized with the target probe in the HybEZ oven for 2 hours at 40°C. After two washes, the samples were processed for a series of signal amplification steps. Chromogenic detection was performed using DAB, counterstained with 50%
Gill's Hematoxylin I (Fisher Scientific, Rochester, NY).
Quantitative RT-PCR
Pancreatic total RNA was isolated using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen).
For quantitation of mRNA transcripts, RNA was extracted from the indicated samples, and cDNA was synthesized using the SuperScript III System according to the manufacturer's instructions (Invitrogen). Quantitative RT-PCR was conducted using primers detailed in Supplementary Table 3 with SYBR Green Master Mix (Applied Biosystems) on the StepOne
Real-Time PCR System (Applied Biosystems). Relative mRNA levels of the transcripts were normalized to the expression of the housekeeping gene GAPDH.
Pancreatic tissue lysates and immunoblot analysis
Pancreata obtained from mice were homogenized in Mg 2+ -containing lysis buffer. Clear lysates were separated using SDS-PAGE and processed for immunoblot analysis using standard methods. Primary antibodies used in the study are indicated in Supplementary Table 1 .
Particularly, Ras antibodies validated in a recent study 29 are also indicated. ;p48Cre mice were cultured in organoid media as described previously 35 .
Isolation of pancreatic ductal organoids
Organoids were cultured without EGF for 9 passages to exclude normal duct contamination, which are dependent on EGF.
RAS-GTP analysis
Protein lysates were prepared from pancreatic ductal organoids or cell lines using Mg 2+ -containing lysis buffer. RAF1 binding was used as a measure of RAS-GTP levels in the lysates, as previously described 15 .
Plasmids
Full length FH-AGO2 constructs were obtained from Addgene (pIRESneo-FLAG/HA-AGO2 10822, PI:Thomas Tuschl). AGO2 Y393F mutant construct was generated using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) from the FH-AGO2 plasmid described above using the primers hAGO2_Y393F_Fwd
5'AAATTCACGGACGAATGGATCTGTGTTGAAACTTGCAC3' and hAGO2_Y393F_Rev
5'GTGCAAGTTTCAACACAGATCCATTCGTCCGTGAATTT3'. DNA sequences were confirmed using Sanger sequencing at the University of Michigan Sequencing Core.
Cell culture, transfection, and EGF stimulation
All cell lines (detailed in Supplementary 
Immunoprecipitation (IP) Analysis
For immunoprecipitation analysis, protein lysates were prepared in K Buffer (20 mM Tris pH 7.0, 
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